Jean-François Fonteneau Selected Research

Peptides (Polypeptides)

10/2023	Oncolytic attenuated measles virus encoding NY-ESO-1 induces HLA I and II presentation of this tumor antigen by melanoma and dendritic cells.
2/2014	A spliced antigenic peptide comprising a single spliced amino acid is produced in the proteasome by reverse splicing of a longer peptide fragment followed by trimming.
6/2013	Requirement of tumor-associated antigen-specific CD4+ T cells for an efficient dendritic cell vaccine in antitumor immunotherapy.
10/2007	A HLA-DQ5 restricted Melan-A/MART-1 epitope presented by melanoma tumor cells to CD4+ T lymphocytes.
9/2007	Synthesis of glycocluster-tumor antigenic peptide conjugates for dendritic cell targeting.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jean-François Fonteneau Research Topics

Disease

31	Neoplasms (Cancer) 04/2024 - 09/2005
9	Melanoma (Melanoma, Malignant) 10/2023 - 09/2007
8	Mesothelioma 12/2022 - 12/2015
7	Malignant Mesothelioma 01/2020 - 03/2012
5	Infections 10/2023 - 05/2003
2	Testicular Neoplasms (Testicular Cancer) 10/2023 - 03/2012
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2024
1	Lung Neoplasms (Lung Cancer) 04/2024
1	Measles 10/2023
1	Hypersensitivity (Allergy) 07/2017
1	Porcine Reproductive and Respiratory Syndrome (PRRS) 01/2017
1	Pleural Effusion (Pleural Effusions) 10/2016
1	Adenocarcinoma of Lung 06/2014
1	Colorectal Neoplasms (Colorectal Cancer) 01/2013
1	Hodgkin Disease (Hodgkin's Disease) 09/2005
1	Nasopharyngeal Carcinoma 09/2005

Drug/Important Bio-Agent (IBA)

8	AntigensIBA 10/2023 - 09/2005
6	Interferon Type IIBA 12/2022 - 12/2015
6	VaccinesIBA 06/2013 - 10/2007
5	Proteins (Proteins, Gene)FDA Link 04/2024 - 02/2014
5	Peptides (Polypeptides)IBA 10/2023 - 09/2007
5	Neoplasm Antigens (Tumor Antigens)IBA 10/2023 - 01/2013
4	AsbestosIBA 12/2022 - 10/2016
4	EpitopesIBA 06/2013 - 09/2007
3	ruxolitinibIBA 12/2022 - 01/2017
3	MART-1 AntigenIBA 05/2008 - 09/2007
2	MicroRNAs (MicroRNA)IBA 01/2022 - 01/2020
2	InterferonsIBA 01/2021 - 01/2017
2	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2020 - 01/2017
2	CytokinesIBA 01/2020 - 01/2020
2	Cisplatin (Platino)FDA LinkGeneric 01/2020 - 06/2014
2	ChemokinesIBA 10/2016 - 05/2003
2	Differentiation AntigensIBA 05/2008 - 10/2007
1	3' Untranslated Regions (3' UTR)IBA 12/2022
1	Adenosine DeaminaseIBA 12/2022
1	Nucleic AcidsIBA 12/2022
1	Diuron (DCMU)IBA 01/2022
1	RNA (Ribonucleic Acid)IBA 01/2022
1	salicylhydroxamic acid (SHAM)IBA 01/2021
1	Janus Kinase InhibitorsIBA 01/2021
1	Double-Stranded RNA (RNA, Double Stranded)IBA 01/2021
1	Yellow Fever Vaccine (Vaccine, Yellow Fever)FDA Link 12/2020
1	Poly I-CIBA 01/2020
1	Antiviral Agents (Antivirals)IBA 01/2020
1	Toll-Like Receptor 3IBA 01/2020
1	Macrophage Colony-Stimulating FactorIBA 01/2020
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2020
1	Granzymes (Granzyme)IBA 01/2020
1	Death Domain ReceptorsIBA 01/2020
1	HLA-DPw4 antigenIBA 01/2018
1	Attenuated VaccinesIBA 01/2017
1	Pattern Recognition ReceptorsIBA 01/2017
1	LigandsIBA 10/2016
1	Monoclonal AntibodiesIBA 03/2015
1	Messenger RNA (mRNA)IBA 06/2014
1	Histone Deacetylase InhibitorsIBA 06/2014
1	Vorinostat FDA Link 06/2014
1	HLA-A3 Antigen (HLA A3 Antigen)IBA 02/2014
1	Complement System Proteins (Complement)IBA 03/2013
1	Antineoplastic Agents (Antineoplastics)IBA 03/2013
1	Caspase 3 (Caspase-3)IBA 01/2013
1	Glycoproteins (Glycoprotein)IBA 01/2013
1	HLA-DQ5 antigenIBA 10/2007
1	Cancer VaccinesIBA 09/2007

Therapy/Procedure

8	Therapeutics 04/2024 - 03/2012
8	Immunotherapy 09/2020 - 10/2007
3	Drug Therapy (Chemotherapy) 04/2024 - 01/2020
1	Transplantation 06/2016
1	Oncolytic Virotherapy 01/2015